z-logo
Premium
Comparison of the therapeutic effects of narrow band UVB vs. PUVA in patients with pityriasis lichenoides
Author(s) -
Farnaghi F.,
Seirafi H.,
Ehsani A.H.,
Agdari M.E.,
Noormohammadpour P.
Publication year - 2011
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2010.03879.x
Subject(s) - medicine , contraindication , dermatology , ultraviolet b , puva therapy , therapeutic effect , randomization , ultraviolet therapy , randomized controlled trial , psoriasis , pathology , alternative medicine
Background and aims  Pityriasis lichenoides (PL) is a self‐limiting papulosquamous skin disorder with chronic course. Best therapeutic options are yet to be defined. Phototherapy is one of the most prevalent treatments and the aim of this study was to compare the therapeutic effects of the two main phototherapy options: psoralen plus ultraviolet A (PUVA) and narrow band UVB (NB‐UVB). Material and methods  Patients with PLC based on clinical findings and pathology, involving at least 60% of total body surface, were enrolled if they were not pregnant, lactating women and had not contraindication for phototherapy. Based on simple randomization, they received either PUVA or NB‐UVB, and patients’ responses were recorded. Results  A total of 15 patients including eight males (53%) and seven females (47%) were enrolled in the study and were randomized into groups A and B, each including four patients. In group A, seven patients had complete response (87.5%) and one patient had partial response (12.5%). Among patients in group B, five patients had complete response (71.4%) and two patients (28.6%) had partial response ( P  > 0.05). Conclusion  As the difference between the two groups is insignificant, it seems that both options are acceptable for treating this disorder.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here